🔗 Share this article US and UK Strike Zero-Tariff Arrangement on Medicines. Representative image of drug trade. The UK and US have signed a major commercial pact that will ensure zero tariffs on UK pharmaceutical exports being sold in the US market. Key Provisions of the Pact As part of the deal, the UK has pledged to raise funding on medicines through the NHS. This move secures that tariffs on these vital goods will stay at zero for a duration of 36 months. This agreement follows earlier warnings to hike tariffs on patented drug products, with increases floated reaching one hundred percent. "This deal between the United Kingdom bolsters the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a statement said. Economic Importance Medicines represent one of the Britain's largest exports to the United States, which is clearly the biggest destination for major UK drugmakers. Export figures reveal that in the 12 months leading up to last September, the UK shipped medicines worth over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that timeframe. "This agreement safeguards employment, increases funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated. Detailed NHS Changes The deal entails several key commitments from the UK: Revised Affordability Limit: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%. Boosted Medicine Funding: There is a target to increase overall public funding on medicines from 0.3% of GDP to 0.6% over the following ten-year period. Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, repayments were more than 20%. Broader Context The deal follows a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates. The disagreement were exacerbated by claims that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU. In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward US facilities. A senior figure publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
Representative image of drug trade. The UK and US have signed a major commercial pact that will ensure zero tariffs on UK pharmaceutical exports being sold in the US market. Key Provisions of the Pact As part of the deal, the UK has pledged to raise funding on medicines through the NHS. This move secures that tariffs on these vital goods will stay at zero for a duration of 36 months. This agreement follows earlier warnings to hike tariffs on patented drug products, with increases floated reaching one hundred percent. "This deal between the United Kingdom bolsters the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a statement said. Economic Importance Medicines represent one of the Britain's largest exports to the United States, which is clearly the biggest destination for major UK drugmakers. Export figures reveal that in the 12 months leading up to last September, the UK shipped medicines worth over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that timeframe. "This agreement safeguards employment, increases funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated. Detailed NHS Changes The deal entails several key commitments from the UK: Revised Affordability Limit: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%. Boosted Medicine Funding: There is a target to increase overall public funding on medicines from 0.3% of GDP to 0.6% over the following ten-year period. Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, repayments were more than 20%. Broader Context The deal follows a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates. The disagreement were exacerbated by claims that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU. In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward US facilities. A senior figure publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.